The U.S. FDA has approved Eli Lilly's (NYSE:LLY) donanemab as a treatment for early Alzheimer's disease. The therapy, which is given via infusion once a month, will be marketed under the name Kisunla....
Source LinkThe U.S. FDA has approved Eli Lilly's (NYSE:LLY) donanemab as a treatment for early Alzheimer's disease. The therapy, which is given via infusion once a month, will be marketed under the name Kisunla....
Source Link
Comments